Business
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
Company's IP estate includes approximately 200 patents issued and pendingSAN FRANCISCO, CA / ACCESSWIRE / February 23, 2023 / Jaguar Health, Inc.
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Company's IP estate includes approximately 200 patents issued and pendingSAN FRANCISCO, CA / ACCESSWIRE / February 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/617,466, titled Methods And Compositions For Treating Bile Acid Diarrhea, Diarrhea Associated With Small Intestine Resection Or Gallbladder Removal, And Short Bowel Syndrome.\"We are very pleased to receive this Notice of Allowance from the USPTO. This Notice of Allowance is expected to conclude the substantive examination of this crofelemer-related patent application and result in the issuance of a U.S. patent after administrative processes are completed,\" said Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research, and IP Officer. \"Jaguar holds extensive global rights for our crofelemer drug product, comprising a valuable and significant barrier to entry. The Company currently holds approximately 145 issued patents, with coverage in many cases that extends until 2031. These issued patents cover multiple indications including HIV/AIDS-related diarrhea, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS), as well as important manufacturing processes and other key Company intellectual property. We also currently have approximately 55 pending patent applications worldwide in human health areas that are being prosecuted.\"Mytesi® (crofelemer) is the Company's antidiarrheal prescription drug approved by the U.S. Food and Drug Administration (FDA) for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. It is the only oral drug approved by the FDA under botanical guidance, providing additional exclusivity advantages.About CrofelemerCrofelemer is an oral botanical (plant-based) drug extracted and purified from the red bark sap, also referred to as \"dragon's blood,\" of the Croton lechleri tree in the Amazon Rainforest. The Company has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities. As stated on the FDA's website, crofelemer is currently one of only two drugs that h...